FDA Recall Terminated

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

Recall: Z-0267-2018 · Initiated December 9, 2016

Recall

Recall Number
Z-0267-2018
Event Number
77439
Firm
C.R. Bard, Inc.
FEI Number
1018233
Product Code
KXK
Status
Terminated
Root Cause
Other
Initiated
December 9, 2016
Terminated
April 24, 2020
Address
8195 Industrial Blvd NE, Covington, GA, 30014-1497

Description

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

Reason

Activity and quantity of seeds sent in shipments were incorrect.

Action

Customers were notified via letter on December 9, 2016. In the case of both customers, the hospital utilized the product to complete the scheduled implants. Adjustments were made to the dose plans and the number of seeds implanted. According to C.R. Bard, the physicians would evaluate the risk by taking into account each individual patient's condition, comorbidities, and treatment plans, and would adjust the dose. For further questions, please call (770) 784-6120.

Distribution

Belgium & South Africa.

Quantity

134 seeds